Blockade of interleukin-6 signalling with siltuximab enhances melphalan cytotoxicity in preclinical models of multiple myeloma

British Journal of Haematology

Volumn 152, Issue 5, 2011, Pages 579-592

  Hunsucker, Sally A ^a   Magarotto, Valeria ^a   Kuhn, Deborah J ^a   Kornblau, Steven M ^a   Wang, Michael ^a   Weber, Donna M ^a   Thomas, Sheeba K ^a   Shah, Jatin J ^a   Voorhees, Peter M ^b   Xie, Hong ^c   Cornfeld, Mark ^c   Nemeth, Jeffrey A ^c   Orlowski, Robert Z ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

^c CENTOCOR INC   (United States)

Author keywords

Akt; Interleukin 6; Melphalan; Multiple myeloma; Siltuximab

Indexed keywords

ANTINEOPLASTIC AGENT; CASPASE 3; CASPASE 8; CASPASE 9; F 105; INITIATION FACTOR 4E BINDING PROTEIN 1; INTERLEUKIN 6; MELPHALAN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN BAK; PROTEIN BAX; PROTEIN KINASE B; S6 KINASE; SILTUXIMAB; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RESISTANCE; CELL DEATH; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DRUG POTENTIATION; ENZYME ACTIVATION; HUMAN; HUMAN CELL; HUMAN TISSUE; MULTIPLE MYELOMA; MYELOMA CELL; PRIORITY JOURNAL; PROTEIN CLEAVAGE; RADIOIMMUNOPRECIPITATION;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BCL-2 HOMOLOGOUS ANTAGONIST-KILLER PROTEIN; BCL-2-ASSOCIATED X PROTEIN; BH3 INTERACTING DOMAIN DEATH AGONIST PROTEIN; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; INTERLEUKIN-6; MELPHALAN; MULTIPLE MYELOMA; NEOPLASM PROTEINS; PLASMA CELLS; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; TUMOR CELLS, CULTURED;

EID: 79951556761     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2010.08533.x     Document Type: Article

References (54)

1. Baumann, P., Mandl-Weber, S., Oduncu, F. & Schmidmaier, R. (2009) The novel orally bioavailable inhibitor of phosphoinositol-3-kinase and mammalian target of rapamycin, NVP-BEZ235, inhibits growth and proliferation in multiple myeloma. Experimental Cell Research, 315, 485-497.
2. Bellamy, W.T., Dalton, W.S., Gleason, M.C., Grogan, T.M. & Trent, J.M. (1991) Development and characterization of a melphalan-resistant human multiple myeloma cell line. Cancer Research, 51, 995-1002.
3. Chen, Q., Van der Sluis, P.C., Boulware, D., Hazlehurst, L.A. & Dalton, W.S. (2005) The FA/BRCA pathway is involved in melphalan-induced DNA interstrand cross-link repair and accounts for melphalan resistance in multiple myeloma cells. Blood, 106, 698-705.
4. Cheng, E.H., Wei, M.C., Weiler, S., Flavell, R.A., Mak, T.W., Lindsten, T. & Korsmeyer, S.J. (2001) BCL-2, BCL-X(L) sequester BH3 domain-only molecules preventing BAX- and BAK-mediated mitochondrial apoptosis. Molecular Cell, 8, 705-711.
5. Chipuk, J.E. & Green, D.R. (2008) How do BCL-2 proteins induce mitochondrial outer membrane permeabilization? Trends in Cell Biology, 18, 157-164.
6. Condomines, M., Veyrune, J.L., Larroque, M., Quittet, P., Latry, P., Lugagne, C., Hertogh, C., Kanouni, T., Rossi, J.F. & Klein, B. (2010) Increased plasma-immune cytokines throughout the high-dose melphalan-induced lymphodepletion in patients with multiple myeloma: a window for adoptive immunotherapy. Journal of Immunology, 184, 1079-1084.
7. Datta, S.R., Dudek, H., Tao, X., Masters, S., Fu, H., Gotoh, Y. & Greenberg, M.E. (1997) Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell, 91, 231-241.
8. Derenne, S., Monia, B., Dean, N.M., Taylor, J.K., Rapp, M.J., Harousseau, J.L., Bataille, R. & Amiot, M. (2002) Antisense strategy shows that Mcl-1 rather than Bcl-2 or Bcl-x(L) is an essential survival protein of human myeloma cells. Blood, 100, 194-199.
9. Dimopoulos, M.A., Kastritis, E. & Rajkumar, S.V. (2008) Treatment of plasma cell dyscrasias with lenalidomide. Leukemia, 22, 1343-1353.
10. Downward, J. (2004) PI 3-kinase, Akt and cell survival. Seminars in Cell & Developmental Biology, 15, 177-182.
11. Fulciniti, M., Hideshima, T., Vermot-Desroches, C., Pozzi, S., Nanjappa, P., Shen, Z., Patel, N., Smith, E.S., Wang, W., Prabhala, R., Tai, Y.T., Tassone, P., Anderson, K.C. & Munshi, N.C. (2009) A high-affinity fully human anti-IL-6 mAb, 1339, for the treatment of multiple myeloma. Clinical Cancer Research, 15, 7144-7152.
12. Gomez-Bougie, P., Oliver, L., Le Gouill, S., Bataille, R. & Amiot, M. (2005) Melphalan-induced apoptosis in multiple myeloma cells is associated with a cleavage of Mcl-1 and Bim and a decrease in the Mcl-1/Bim complex. Oncogene, 24, 8076-8079.
13. Green, D.R. & Kroemer, G. (2004) The pathophysiology of mitochondrial cell death. Science, 305, 626-629.
14. Greipp, P.R., Leong, T., Bennett, J.M., Gaillard, J.P., Klein, B., Stewart, J.A., Oken, M.M., Kay, N.E., Van Ness, B. & Kyle, R.A. (1998) Plasmablastic morphology - an independent prognostic factor with clinical and laboratory correlates: Eastern Cooperative Oncology Group (ECOG) myeloma trial E9486 report by the ECOG Myeloma Laboratory Group. Blood, 91, 2501-2507.
15. Hamasaki, M., Hideshima, T., Tassone, P., Neri, P., Ishitsuka, K., Yasui, H., Shiraishi, N., Raje, N., Kumar, S., Picker, D.H., Jacob, G.S., Richardson, P.G., Munshi, N.C. & Anderson, K.C. (2005) Azaspirane (N-N-diethyl-8, 8-dipropyl-2-azaspiro [4.5] decane-2-propanamine) inhibits human multiple myeloma cell growth in the bone marrow milieu in vitro and in vivo. Blood, 105, 4470-4476.
16. Hideshima, T., Nakamura, N., Chauhan, D. & Anderson, K.C. (2001) Biologic sequelae of interleukin-6 induced PI3-K/Akt signaling in multiple myeloma. Oncogene, 20, 5991-6000.
17. Hideshima, T., Catley, L., Yasui, H., Ishitsuka, K., Raje, N., Mitsiades, C., Podar, K., Munshi, N.C., Chauhan, D., Richardson, P.G. & Anderson, K.C. (2006) Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells. Blood, 107, 4053-4062.
18. Hideshima, T., Mitsiades, C., Tonon, G., Richardson, P.G. & Anderson, K.C. (2007) Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets. Nature Reviews Cancer, 7, 585-598.
19. Hodge, D.R., Peng, B., Cherry, J.C., Hurt, E.M., Fox, S.D., Kelley, J.A., Munroe, D.J. & Farrar, W.L. (2005) Interleukin 6 supports the maintenance of p53 tumor suppressor gene promoter methylation. Cancer Research, 65, 4673-4682.
20. Hulin, C., Facon, T., Rodon, P., Pegourie, B., Benboubker, L., Doyen, C., Dib, M., Guillerm, G., Salles, B., Eschard, J.P., Lenain, P., Casassus, P., Azais, I., Decaux, O., Garderet, L., Mathiot, C., Fontan, J., Lafon, I., Virion, J.M. & Moreau, P. (2009) Efficacy of melphalan and prednisone plus thalidomide in patients older than 75years with newly diagnosed multiple myeloma: IFM 01/01 trial. Journal of Clinical Oncology, 27, 3664-3670.
21. Kroczynska, B., Kaur, S. & Platanias, L.C. (2009) Growth suppressive cytokines and the AKT/mTOR pathway. Cytokine, 48, 138-143.
22. Kuhn, D.J., Chen, Q., Voorhees, P.M., Strader, J.S., Shenk, K.D., Sun, C.M., Demo, S.D., Bennett, M.K., van Leeuwen, F.W., Chanan-Khan, A.A. & Orlowski, R.Z. (2007) Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma. Blood, 110, 3281-3290.
23. Kuhn, D.J., Hunsucker, S.A., Chen, Q., Voorhees, P.M., Orlowski, M. & Orlowski, R.Z. (2009) Targeted inhibition of the immunoproteasome is a potent strategy against models of multiple myeloma that overcomes resistance to conventional drugs and nonspecific proteasome inhibitors. Blood, 113, 4667-4676.
24. Laubach, J.P., Mahindra, A., Mitsiades, C.S., Schlossman, R.L., Munshi, N.C., Ghobrial, I.M., Carreau, N., Hideshima, T., Anderson, K.C. & Richardson, P.G. (2009) The use of novel agents in the treatment of relapsed and refractory multiple myeloma. Leukemia, 23, 2222-2232.
25. Leber, B., Lin, J. & Andrews, D.W. (2007) Embedded together: the life and death consequences of interaction of the Bcl-2 family with membranes. Apoptosis, 12, 897-911.
26. Lindsten, T., Ross, A.J., King, A., Zong, W.X., Rathmell, J.C., Shiels, H.A., Ulrich, E., Waymire, K.G., Mahar, P., Frauwirth, K., Chen, Y., Wei, M., Eng, V.M., Adelman, D.M., Simon, M.C., Ma, A., Golden, J.A., Evan, G., Korsmeyer, S.J., MacGregor, G.R. & Thompson, C.B. (2000) The combined functions of proapoptotic Bcl-2 family members bak and bax are essential for normal development of multiple tissues. Molecular Cell, 6, 1389-1399.
27. Majewski, N., Nogueira, V., Robey, R.B. & Hay, N. (2004) Akt inhibits apoptosis downstream of BID cleavage via a glucose-dependent mechanism involving mitochondrial hexokinases. Molecular and Cellular Biology, 24, 730-740.
28. Merchionne, F., Perosa, F. & Dammacco, F. (2007) New therapies in multiple myeloma. Clinical and Experimental Medicine, 7, 83-97.
29. Moreau, P., Harousseau, J.L., Wijdenes, J., Morineau, N., Milpied, N. & Bataille, R. (2000) A combination of anti-interleukin 6 murine monoclonal antibody with dexamethasone and high-dose melphalan induces high complete response rates in advanced multiple myeloma. British Journal of Haematology, 109, 661-664.
30. Nishimoto, N., Kanakura, Y., Aozasa, K., Johkoh, T., Nakamura, M., Nakano, S., Nakano, N., Ikeda, Y., Sasaki, T., Nishioka, K., Hara, M., Taguchi, H., Kimura, Y., Kato, Y., Asaoku, H., Kumagai, S., Kodama, F., Nakahara, H., Hagihara, K., Yoshizaki, K. & Kishimoto, T. (2005) Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman disease. Blood, 106, 2627-2632.
31. Palumbo, A. & Rajkumar, S.V. (2009) Treatment of newly diagnosed myeloma. Leukemia, 23, 449-456.
32. Palumbo, A., Dimopoulos, M.A., Delforge, M., Kropff, M., Foa, R., Yu, Z., Herbein, L., Mei, J., Jacques, C. & Catalano, J. (2009) A phase III study to determine the efficacy and safety of lenalidomide in combination with melphalan and prednisone (MPR) in elderly patients with newly diagnosed multiple myeloma. Blood, 114, Abstract-613.
33. Pei, X.Y., Dai, Y., Tenorio, S., Lu, J., Harada, H., Dent, P. & Grant, S. (2007) MEK1/2 inhibitors potentiate UCN-01 lethality in human multiple myeloma cells through a Bim-dependent mechanism. Blood, 110, 2092-2101.
34. Portier, M., Rajzbaum, G., Zhang, X.G., Attal, M., Rusalen, C., Wijdenes, J., Mannoni, P., Maraninchi, D., Piechaczyk, M., Bataille, R. & Klein, B. (1991) In vivo interleukin 6 gene expression in the tumoral environment in multiple myeloma. European Journal of Immunology, 21, 1759-1762.
35. Puchalski, T., Prabhakar, U., Jiao, Q., Berns, B. & Davis, H.M. (2010) Pharmacokinetic and pharmacodynamic modeling of an anti-interleukin-6 chimeric monoclonal antibody (siltuximab) in patients with metastatic renal cell carcinoma. Clinical Cancer Research, 16, 1652-1661.
36. Rossi, J.F., Fegueux, N., Lu, Z.Y., Legouffe, E., Exbrayat, C., Bozonnat, M.C., Navarro, R., Lopez, E., Quittet, P., Daures, J.P., Rouille, V., Kanouni, T., Widjenes, J. & Klein, B. (2005) Optimizing the use of anti-interleukin-6 monoclonal antibody with dexamethasone and 140mg/m2 of melphalan in multiple myeloma: results of a pilot study including biological aspects. Bone Marrow Transplantation, 36, 771-779.
37. Rossi, J.-F., Manges, R.F., Sutherland, H.J., Jagannath, S., Voorhees, P., Sonneveld, P., Delforge, M., Pegourie, B., Alegre, A., de la Rubia, J., La Police, D., Bandekar, R., Xie, H. & Orlowski, R.Z. (2008) Preliminary results of CNTO 328, an anti-interleukin-6 monoclonal antibody, in combination with bortezomib in the treatment of relapsed or refractory multiple myeloma. Blood, 112, Abstract-867.
38. Scaffidi, C., Fulda, S., Srinivasan, A., Friesen, C., Li, F., Tomaselli, K.J., Debatin, K.M., Krammer, P.H. & Peter, M.E. (1998) Two CD95 (APO-1/Fas) signaling pathways. EMBO Journal, 17, 1675-1687.
39. Shah, J.J. & Orlowski, R.Z. (2009) Proteasome inhibitors in the treatment of multiple myeloma. Leukemia, 23, 1964-1979.
40. Sheridan, C. & Martin, S.J. (2008) Commitment in apoptosis: slightly dead but mostly alive. Trends in Cell Biology, 18, 353-357.
41. Spanswick, V.J., Craddock, C., Sekhar, M., Mahendra, P., Shankaranarayana, P., Hughes, R.G., Hochhauser, D. & Hartley, J.A. (2002) Repair of DNA interstrand crosslinks as a mechanism of clinical resistance to melphalan in multiple myeloma. Blood, 100, 224-229.
42. Stasi, R., Brunetti, M., Parma, A., Di Giulio, C., Terzoli, E. & Pagano, A. (1998) The prognostic value of soluble interleukin-6 receptor in patients with multiple myeloma. Cancer, 82, 1860-1866.
43. Stuhmer, T., Chatterjee, M., Hildebrandt, M., Herrmann, P., Gollasch, H., Gerecke, C., Theurich, S., Cigliano, L., Manz, R.A., Daniel, P.T., Bommert, K., Vassilev, L.T. & Bargou, R.C. (2005) Nongenotoxic activation of the p53 pathway as a therapeutic strategy for multiple myeloma. Blood, 106, 3609-3617.
44. Sunters, A., Springer, C.J., Bagshawe, K.D., Souhami, R.L. & Hartley, J.A. (1992) The cytotoxicity, DNA crosslinking ability and DNA sequence selectivity of the aniline mustards melphalan, chlorambucil and 4-[bis(2-chloroethyl)amino] benzoic acid. Biochemical Pharmacology, 44, 59-64.
45. Tassone, P., Neri, P., Carrasco, D.R., Burger, R., Goldmacher, V.S., Fram, R., Munshi, V., Shammas, M.A., Catley, L., Jacob, G.S., Venuta, S., Anderson, K.C. & Munshi, N.C. (2005) A clinically relevant SCID-hu in vivo model of human multiple myeloma. Blood, 106, 713-716.
46. Teoh, G., Tai, Y.T., Urashima, M., Shirahama, S., Matsuzaki, M., Chauhan, D., Treon, S.P., Raje, N., Hideshima, T., Shima, Y. & Anderson, K.C. (2000) CD40 activation mediates p53-dependent cell cycle regulation in human multiple myeloma cell lines. Blood, 95, 1039-1046.
47. Trikha, M., Corringham, R., Klein, B. & Rossi, J.F. (2003) Targeted anti-interleukin-6 monoclonal antibody therapy for cancer: a review of the rationale and clinical evidence. Clinical Cancer Research, 9, 4653-4665.
48. Voorhees, P.M., Chen, Q., Kuhn, D.J., Small, G.W., Hunsucker, S.A., Strader, J.S., Corringham, R.E., Zaki, M.H., Nemeth, J.A. & Orlowski, R.Z. (2007) Inhibition of interleukin-6 signaling with CNTO 328 enhances the activity of bortezomib in preclinical models of multiple myeloma. Clinical Cancer Research, 13, 6469-6478.
49. Voorhees, P.M., Chen, Q., Small, G.W., Kuhn, D.J., Hunsucker, S.A., Nemeth, J.A. & Orlowski, R.Z. (2009) Targeted inhibition of interleukin-6 with CNTO 328 sensitizes pre-clinical models of multiple myeloma to dexamethasone-mediated cell death. British Journal of Haematology, 145, 481-490.
50. Wierzbowska, A., Urbanska-Rys, H. & Robak, T. (1999) Circulating IL-6-type cytokines and sIL-6R in patients with multiple myeloma. British Journal of Haematology, 105, 412-419.
51. Willis, S.N., Chen, L., Dewson, G., Wei, A., Naik, E., Fletcher, J.I., Adams, J.M. & Huang, D.C. (2005) Proapoptotic Bak is sequestered by Mcl-1 and Bcl-xL, but not Bcl-2, until displaced by BH3-only proteins. Genes and Development, 19, 1294-1305.
52. Willis, S.N., Fletcher, J.I., Kaufmann, T., van Delft, M.F., Chen, L., Czabotar, P.E., Ierino, H., Lee, E.F., Fairlie, W.D., Bouillet, P., Strasser, A., Kluck, R.M., Adams, J.M. & Huang, D.C. (2007) Apoptosis initiated when BH3 ligands engage multiple Bcl-2 homologs, not Bax or Bak. Science, 315, 856-859.
53. Yoshio-Hoshino, N., Adachi, Y., Aoki, C., Pereboev, A., Curiel, D.T. & Nishimoto, N. (2007) Establishment of a new interleukin-6 (IL-6) receptor inhibitor applicable to the gene therapy for IL-6-dependent tumor. Cancer Research, 67, 871-875.
54. Zhang, B., Gojo, I. & Fenton, R.G. (2002) Myeloid cell factor-1 is a critical survival factor for multiple myeloma. Blood, 99, 1885-1893.